“Dimethyl Fumarate Tested on the ARSACS Mouse Model” – Drs. Wolter & Wang

This project, led by Drs. Justin Wolter and Huaxia Wang, aims to test the therapeutic potential of dimethyl fumarate (DMF) in the ARSACS mouse model. DMF is currently approved for the treatment of multiple sclerosis (MS), where it has been shown to reduce neuroinflammation, oxidative stress, and neuronal death. Additionally, DMF has been tested in preclinical models of other neurodegenerative diseases, such as amyotrophic lateral sclerosis, Parkinson’s disease, and Alzheimer’s disease, where it demonstrates promising neuroprotective effects. In our study, we will evaluate the therapeutic potential of DMF in the ARSACS mouse model, testing motor function and molecular markers of neuroinflammation, oxidative stress, and neurodegeneration. Successful results could pave the way for DMF-based treatments in future ARSACS clinical trials, and determine the utility of specific biomarkers in tracking ARSACS progression.